混合基本面是否会对龙沙集团(VTX:LONN)当前股价走势产生负面影响?- 雅虎财经
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? - Yahoo Finance
生物技术与制药领域的最新动态
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? - Yahoo Finance
Q&A: Large-scale commercial expansion at Lonza’s Stein facility - Fierce Pharma
Lonza to buy rapid microbial testing firm Redberry SAS - Fierce Biotech
Bristol in Friendswood to break ground in coming months; Lonza plans renovation in Pearland - Community Impact | News
Lonza to Acquire Redberry SAS - Contract Pharma
Lonza to expand bioscience testing offering with the acquisition of Redberry - Drug Discovery News
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site - Investing.com
Earnings call transcript: Lonza Group Q3 2025 sees strong CDMO growth - Investing.com
Lonza's recently purchased Calif. biologics site plays key role in sales rebound - Fierce Pharma
Lonza Reports Strong Q3 2025 and Confirms Full-Year Outlook - TipRanks
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses - TradingView
Lonza confirms outlook as it expects more contracts in coming months - Reuters
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) - Technology Networks
CPHI 2025: Lonza Capsugel spotlights delivery tech and sustainability in nutraceuticals - nutritioninsight.com
GBCC and Lonza partner for apprenticeship program - NH Business Review
Lonza expands its GMP solutions for cell and gene therapy - SelectScience
Lonza Capsugel launches organic, vegan capsule line - SupplySide Supplement Journal
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) - the-scientist.com
Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)? - Yahoo Finance
Lonza Group: Growth, Signs Of Overvaluation, And A New Management Cause Uncertainty - Seeking Alpha